Skip to main content
Premium Trial:

Request an Annual Quote

Vitro, HemoGenix Amend Cell-based Assay Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vitro Diagnostics today announced that it has amended an agreement with HemoGenix covering stem cell analysis tools.

The amended agreement expands upon the original agreement to include development of stem cell culture media and high-performance toxicity assays for new cell-based tools for drug discovery and development. The firms also intend to align their respective quality programs to assure consistency, said Golden, Colo.-based Vitro.

The partners will further develop Vitro's Vitrogrow cell culture medium, human hepatocytes, and industrially-adopted bioluminescent readout system for detecting liver toxicity and drug-induced liver injury in drugs and biologics that are in the development stage. The partners also intend to expand HemoGenix's LumiSTEM platform for other cell-specific toxicity assays such as heart, kidney, and neuronal cells.

Financial and other terms of the agreement were not disclosed.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.